Notice for lenacapavir (Gilead Sciences Pty Ltd)
Active ingredients
lenacapavir
Sponsor
Date of review outcome
Lapse date
Type
Priority review
Indication
[TRADENAME], in combination with other antiretroviral(s), is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and pediatrics weighing at least 35 kg with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen due to resistance, intolerance, or safety considerations.
Therapeutic area
Infectious diseases